TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Medicus Pharma Ltd ( (MDCX) ) is now available.
On November 14, 2025, Medicus Pharma Ltd. announced its financial and operating results for the quarter ending September 30, 2025, alongside significant corporate updates. The company has made progress in its clinical development programs, particularly with the SkinJect platform for treating basal cell carcinoma and the acquisition of Antev Limited, which enhances its drug development pipeline. Financially, the company reported a net loss of $16 million for the third quarter, reflecting increased expenses due to accelerated clinical programs and strategic acquisitions. The company’s balance sheet remains strong with $8.7 million in cash and cash equivalents, bolstered by $10.4 million from financing transactions.
The most recent analyst rating on (MDCX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.
Spark’s Take on MDCX Stock
According to Spark, TipRanks’ AI Analyst, MDCX is a Underperform.
Medicus Pharma Ltd’s financial difficulties, characterized by the absence of revenue and consistent losses, are the most significant concerns. While technical indicators show some positive momentum, the negative valuation metrics underscore investor caution about long-term profitability.
To see Spark’s full report on MDCX stock, click here.
More about Medicus Pharma Ltd
Medicus Pharma Ltd. is a biotech/life sciences company focused on advancing clinical development programs for novel and potentially disruptive therapeutic assets. The company is actively engaged in multiple countries across three continents and is particularly focused on developing non-invasive treatments for basal cell skin cancer through its subsidiary, SkinJect Inc.
Average Trading Volume: 371,376
Technical Sentiment Signal: Sell
Current Market Cap: $48.92M
Learn more about MDCX stock on TipRanks’ Stock Analysis page.